Equities

Modular Medical Inc

MODD:NAQ

Modular Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.64
  • Today's Change-0.06 / -3.53%
  • Shares traded41.14k
  • 1 Year change+57.69%
  • Beta-0.1686
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Modular Medical, Inc. is a development stage, medical device company. The Company is focused on the design, development, and commercialization of an insulin pump using modernized technology to increase pump adoption in the diabetes marketplace. The Company, through the creation of two-part patch pump, MODD1, seeks to serve both the type 1 and type 2 diabetes markets. The Company, using its methods of insulin measurement, is able to eschew complex mechanisms and instead build a product candidate using only parts from high volume consumer electronics manufacturing lines. It provides an insulin pump, which has both basal (steady flow) and bolus (mealtime dosing) insulin disbursement. It also consists of a natural migration path to multi-chamber/multi-liquid pumps, potentially offering an array of new therapies to patients with diabetes and other conditions.

  • Revenue in USD (TTM)0.00
  • Net income in USD-16.76m
  • Incorporated1998
  • Employees37.00
  • Location
    Modular Medical Inc16772 WEST BERNARDO DRIVESAN DIEGO 92127United StatesUSA
  • Phone+1 (858) 800-3500
  • Fax+1 (775) 786-6755
  • Websitehttps://www.modular-medical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arca Biopharma Inc0.00-6.00m48.02m4.00--1.37-----0.4155-0.41550.002.420.00----0.00-15.24-27.78-15.81-29.38------------0.00------46.21------
IN8BIO, Inc.0.00-31.04m48.10m31.00--2.69-----0.9154-0.91540.000.40490.00----0.00-123.61-74.18-145.63-84.42------------0.0556-------5.21---4.54--
Ocean Biomedical Holdings Inc0.00-45.58m48.86m9.00---------1.40-1.400.00-0.0642------0.00-----------------------------612.50------
Clene Inc.620.00k-48.81m49.20m82.00--11.54--79.36-0.4764-0.47640.00530.03320.01462.119.767,560.98-114.91-39.43-233.02-47.3278.71---7,873.23-5,261.201.22-32.640.8641--38.27---65.47------
Bright Green Corp0.00-11.46m49.65m5.00--4.47-----0.0631-0.06310.000.05840.00----0.00-56.05---84.87-------------18,125.840.0289------52.54------
Kezar Life Sciences Inc7.00m-101.87m49.69m58.00--0.2648--7.10-1.40-1.400.09652.580.0269----120,689.70-39.12-32.54-41.41-34.09-----1,455.29-4,308.11----0.051-------49.28--10.08--
Eagle Pharmaceuticals Inc257.55m11.95m50.00m134.004.230.201.530.19410.9110.91119.5919.250.65491.552.561,922,022.003.046.374.047.9869.8471.864.647.851.673.550.21780.0084.565.99513.14-8.42-49.05--
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Lipocine Inc4.71m-8.97m50.75m17.00--2.11--10.77-1.71-1.710.88894.510.1585--67.70277,138.80-30.16-39.32-32.00-45.87-----190.35-442.26----0.00---670.16---51.99------
Modular Medical Inc0.00-16.76m50.82m37.00--9.08-----0.9653-0.96530.000.18050.00----0.00-224.40-168.16-262.22-209.51------------0.00------25.51--154.53--
DURECT Corp8.32m-23.28m51.21m48.00--6.17--6.15-0.8653-0.86530.29760.26740.1760.70216.87143,465.50-49.23-37.34-167.81-53.4480.5691.83-279.77-139.110.9575-47.700.6377---55.67-10.9621.82---10.98--
BioXcel Therapeutics Inc1.76m-153.05m51.42m74.00------29.28-5.18-5.180.0591-2.150.01340.60675.3123,729.73-116.64-74.57-151.39-84.0624.15---8,715.72-32,300.742.49-15.673.47--268.00---8.02---43.26--
Calcimedica Inc0.00-14.94m52.46m14.00--3.04-----2.64-2.640.001.610.00----0.00-48.34-63.99-66.59-72.71------------0.00------3.51---44.35--
Incannex Healthcare Inc-100.00bn-100.00bn52.70m----3.73----------0.8907-----------54.94---59.47-------1,033.07----0.00--61.923.38-24.35--54.12--
Protara Therapeutics Inc0.00-42.47m52.92m26.00--0.5031-----3.74-3.740.005.110.00----0.00-48.67-37.02-52.23-38.29------------0.00------38.71---17.67--
Data as of Jun 14 2024. Currency figures normalised to Modular Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

42.45%Per cent of shares held by top holders
HolderShares% Held
Manchester Management Co. LLCas of 16 Feb 20243.59m11.60%
Solas Capital Management LLCas of 31 Mar 20241.89m6.10%
683 Capital Management LLCas of 31 Mar 20241.55m4.99%
Sio Capital Management LLCas of 31 Mar 20241.54m4.97%
SilverArc Capital Management LLCas of 31 Mar 2024900.00k2.90%
The Vanguard Group, Inc.as of 31 Mar 2024892.64k2.88%
Bard Associates, Inc.as of 31 Mar 2024824.00k2.66%
AWM Investment Co., Inc.as of 31 Mar 2024750.00k2.42%
Bleichroeder LPas of 31 Mar 2024700.00k2.26%
Corsair Capital Management LPas of 31 Mar 2024520.24k1.68%
More ▼
Data from 31 Mar 2024 - 09 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.